Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to prospectively determine whether capecitabine and
5-FU-induced toxicity is preventable by dose reduction prior to start of the first
administration in patients heterozygous or homozygous mutant for DPYD*2A, and to determine
whether this strategy is cost-effective. Secondly, an individualized treatment algorithm for
capecitabine and 5-FU therapy in DPYD*2A mutant patients will be developed and the
pharmacokinetic profile of capecitabine and 5-FU will be assessed.